ADmit therapeutics is a company that has developed the MAP-AD Test, an IVD that provides a prognosis of progression from MCI to AD dementia. Our IVD is based on the analysis of blood mitochondrial methylcytosines using Next Generation Sequencing techniques and a machine learning approach, providing a prognosis which is not dependent on the b-amyloid or tau determination. The MAP-AD Test has obtained the CE IVDR mark, and the laboratory is certified by the College of American Pathologists.